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ABSTRACT 
 
Alemtuzumab is an anti-CD52 monoclonal antibody recently licensed for use in relapsing-remitting 
multiple sclerosis.  Here we report our experience of its use in neuromyelitis optica (NMO) spectrum 
disorders.   
 
A retrospective case review of patients treated with alemtuzumab in Cambridge, UK, was conducted 
to identify those who fulfil the criteria for NMO spectrum disorder.   Three cases were identified.  Case 
1, 9-year old female, presented with transverse myelitis and bilateral optic neuritis, with one lower 
medullary and several longitudinally extensive cord lesions.  Despite immunosuppression including 
two courses of alemtuzumab, she continued to relapse, was wheelchair bound and registered blind by 
age 12, and died at age 18.  Case 2, 41-year old female, presented with bilateral optic neuritis and 
transverse myelitis with longitudinally extensive cervical cord lesions.  Despite three courses of 
alemtuzumab, she had 5 relapses with visual impairment and new cord lesions.  She later developed 
tumefactive white matter lesions and died aged 51.  Case 3, 31-year old female, presented with 
transverse myelitis with longitudinally extensive cervical cord lesions and positive aquaporin-4 
antibody.  After one course of alemtuzumab, she relapsed with 4 episodes of myelitis with new 
enhancing lesions and accumulating disability.  She became relapse-free after rituximab and 
mycophenolate mofetil.   
 
From this case series we conclude that alemtuzumab failed to prevent disabling relapses and poor 
outcome in NMO.  We Case 3 stabilised with rituximabhypothesise that rituximab is more effective, as 
in Case 3, because it causes much more , the important mechanistic difference being prolonged B 
lymphocyte depletion, which is only depleted for 1-2 months after  than alemtuzumab.  We therefore 
caution against the use of alemtuzumab in NMO. 
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MANUSCRIPT TEXT 
 
Introduction 
 
Alemtuzumab is an anti-CD52 humanised monoclonal antibody recently approved in the European 
Union and by the U.S. Food and Drug Administration as a therapeutic agent in relapsing-remitting 
multiple sclerosis (RRMS). Alemtuzumab induces a profound lymphopaenia; reconstitution of the 
various lymphocyte subsets leads to prolonged modulation of the immune repertoire [1-3].  This leads 
to significant reductions in both relapse frequency and sustained accumulation of disability, compared 
to interferon beta-1a, in RRMS [4-6].   
 
Neuromyelitis optica (NMO) spectrum disorders are a group of syndromes caused by antibodies, 
discovered in 2004 [7], targeting the aquaporin-4 water channel on astrocytic foot  processes [8].  We 
and others have occasionally used alemtuzumab to treat NMO, both before and after NMO was 
recognised as a distinct clinical entity, and here report our experience.  
 
Methods 
 
We conducted a retrospective case review, from 1991 to the present day, of patients treated with 
alemtuzumab at the Department of Neurology in Addenbrooke’s Hospital, Cambridge, UK, to identify 
those patients who fulfil the criteria for NMO spectrum disorder under the revised Wingerchuk criteria  
[9] and the consensus criteria drawn up by the International Panel for NMO Diagnosis convened in 
2011 [10].  The main outcome measures considered were relapse rate, accumulation of disability and 
long-term outcome after alemtuzumab treatment. 
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Results 
 
In retrospect, three cases could be classified as neuromyelitis optica.  One case (case 1) was from the 
1990s; the remaining two were from the early 2000s. 
 
Case 1 
 
A 9-year old girl presented in 1998 with protracted vomiting followed by transverse myelitis, two 
relapses of bilateral optic neuritis and two brainstem episodes (nystagmus, ataxia and facial sensory 
disturbance) within a year.  Imaging showed one lower medullary and several longitudinally extensive 
cord lesions (images no longer available).  Despite high-dose steroids and intensive 
immunosuppression (Table 1), she remained significantly visually impaired (acuities down to 6/60), as 
well as having a spastic paraparesis.  She received alemtuzumab with no relapses for twelve months.  
At month 12 she relapsed with myelitis with longitudinally-extensive thoracic cord demyelination and 
was retreated with alemtuzumab; only weeks later a further relapse resulted in dense paraparesis, 
rendering her wheel-chair bound.  Her vision deteriorated further and she was registered blind by age 
12.  In 2005, her illness was recognised as antibody-mediated NMO [7] and she received plasma 
exchange (PLEX).  She died at age 18, whilst awaiting rituximab treatment. Assays for aquaporin-4 
immunoglobulin-G (AQP4-IgG) were not available at the time. 
 
Case 2 
 
A 41-year old female presented in 2004 with bilateral optic neuritis and a brainstem deficit (left-sided 
horizontal nystagmus and ataxia) and 2 episodes of myelitis within six months; imaging showed 
enhancing brain and longitudinally-extensive cervical cord lesions (Fig 1a-c).  She received pulsed high-
dose steroids and remained with residual spastic paraparesis.  Three cycles of alemtuzumab were 
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administered 12 months apart.  At months 3, 4 and 11 after the first cycle she had discrete relapses 
attributable to new thoracic cord lesions (Fig 1d), whilst cerebral lesions improved (not shown).  At 
months 2 and 9 after second cycle, she relapsed with brainstem symptoms (vertigo and 
incoordination) and bilateral optic neuritis, with residual visual impairment (6/12).  After the third 
cycle she deteriorated with disabling cognitive deficits.  She received rituximab, to no effect, later 
developing seizures and tumefactive white matter lesions (Fig 1e, 1f).  A brain biopsy performed to 
confirm active demyelination showed extensive loss of myelin with numerous CD68+ macrophages 
throughout, but the specific features of neuromyelitis optica were not sought.  She went on to be 
treated with mitoxantrone with poor response.  Late in the course of her illness, as the assay became 
available, she was tested for aquaporin-4 immunoglobulin-G (AQP4-IgG) antibodies, which were 
absent.  She died aged 51.  
 
Case 3  
 
A 31-year old female presented in 2007 with two episodes of transverse myelitis with longitudinally 
extensive cervical cord lesions (Fig 1g, 1h) and tested seropositive for AQP4-IgG antibody.  Two years 
prior, she had a prolonged episode of nausea, vomiting and diplopia that had resolved spontaneously.  
Response to high-dose steroids and PLEX was moderate, with residual paraesthesia, unsteadiness and 
tonic spasms.  She received a single course of alemtuzumab (12mg daily for 5 consecutive days) in an 
attempt to prevent further relapses but at months 3 and 5 after alemtuzumab she represented with 
spastic paraparesis; cord imaging showed disease progression with new enhancing longitudinally-
extensive spinal cord lesions (Fig 1i, 1j).  At months 10 and 18 she had further relapses of myelitis 
without cord enhancement, losing dominant hand function and ability to walk unassisted despite high-
dose steroids and PLEX.  She became relapse-free for 4 years after two cycles of rituximab in 
combination with mycophenolate mofetil (MMF), though disability persists with cord atrophy (Fig 1k).  
Serum AQP4-IgG antibody remained positive after alemtuzumab treatment. 
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Discussion 
We report three cases which demonstrate that alemtuzumab failed to prevent disabling relapses and 
poor outcome in Case 1 and Case 2 are retrospectively described as having NMOSD with unknown 
AQP4-IgG status and NMOSD with negative AQP4-IgG status, respectively.  Both cases presented prior 
to the clinical availability of an AQP4-IgG antibody test.  Stored serum samples from Case 2 were 
tested retrospectively but unfortunately no stored sample from Case 1 is available for retrospective 
testing.  The absence of a positive AQP4-IgG result does not exclude a diagnosis of NMOSD, as per the 
International consensus diagnostic criteria drawn up in 2011 [10].  We feel that both patients would 
fulfil the diagnostic criteria on the basis of two or more core clinical characteristics present and the 
exclusion of alternative diagnoses.  Case 3 was recognised as NMOSD with AQP4-IgG antibody early on 
in the course of illness and was treated with alemtuzumab in an attempt to achieve disease control. 
 
From this small series of three patients, we conclude that, in contrast to alemtuzumab’s high efficacy 
in multiple sclerosis, it is ineffective as a treatment of neuromyelitis optica.  In our experience, 
alemtuzumab failed to prevent disabling relapses and poor outcome in NMO.  In one of our cases 
(case 3), the patient subsequently had a good outcome with rituximab and mycophenolate. The 
important mechanistic difference between alemtuzumab and rituximab is the latter’s prolonged 
depletion of B lymphocytes, which are only depleted for 1-2 months after alemtuzumab. 
 
Although we report the experience from only three cases, the failure of alemtuzumab to control 
neuromyelitis optica. This converges from evidence from other drugs effective in multiple sclerosis 
which also fail to suppress – and indeed may exacerbate – the illness, like interferon beta and 
natalizumab [11,12].  We are aware of two other cases of neuromyelitis optica treated using 
alemtuzumab.  In one, there was no effect on the disease which was subsequently effectively treated 
using an IL-6 antibody [13].  In another, there was a cessation of relapses and reduction in 
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lymphocytes detected in brain lesions pathologically, but the patient deteriorated and died with 
significant monocyte invasion of her brain lesions [14].   
 
All three cases fulfil the criteria for NMO spectrum disorder under the revised Wingerchuk criteria  [9] 
and the International Panel for NMO Diagnosis consesnsus [10]. The authors interpret this as a 
demonstration of the pathogenicity of the innate immune response in neuromyelitis optica, even 
when alemtuzumab had successfully suppressed adaptive immune mechanisms.Case 1 and Case 2 are 
retrospectively described as having NMOSD with unknown AQP4-IgG status and NMOSD with negative 
AQP4-IgG status, respectively.  Both cases 1 and 2 presented prior to the clinical availability of an 
AQP4-IgG antibody test; .  Sstored serum samples from Case 2 were testednegative; case 3 was 
positive in life. 
 retrospectively but unfortunately no stored sample from Case 1 is available for retrospective testing.  
The absence of a positive AQP4-IgG result does not exclude a diagnosis of NMOSD, as per the 
International consensus diagnostic criteria drawn up in 2011 [10].  We feel that both patients would 
fulfil the diagnostic criteria on the basis of two or more core clinical characteristics present and the 
exclusion of alternative diagnoses.  Case 3 was recognised as NMOSD with AQP4-IgG antibody early on 
in the course of illness and was treated with alemtuzumab in an attempt to achieve disease control. 
From this small series of three patients, we conclude that, in contrast to alemtuzumab’s high efficacy 
in multiple sclerosis, it is ineffective as a treatment of neuromyelitis optica.  In our experience, 
alemtuzumab failed to prevent disabling relapses and poor outcome in NMO.   
In one of our cases (case 3), the patient subsequently had a good outcome with rituximab and 
mycophenolate. We hypothesise that the The important mechanistic difference between 
alemtuzumab and rituximab is the latter’s prolonged depletion of B lymphocytes, which are only 
depleted for 1-2 months after alemtuzumab. The use of alemtuzumab is associated with secondary 
autoimmunity, directed mainly against the thyroid, but we do not propose this mechanism for 
continued disease activity of NMO after alemtuzumab.  
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From this case series, and a review of the literature, we therefore caution against the use of 
alemtuzumab in cases of neuromyelitis optica. 
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Figure legend 
 
Fig. 1 MRI images 
Case 2 (a) Pre-treatment T2 weighted axial views show high signal in posterior part of corpus callosum 
and left middle cerebellar peduncle.  (b)  T2 weighted sagittal view of cervical cord shows expansion 
with an extensive lesion from medulla to T1 level, and (c) gadolinium enhancement on T1 weighted 
image.  (d)  Post-treatment T2 weighted sagittal view shows new expansion of thoracic cord between 
T4 and T7with increased T2 signal but no gadolinium enhancement. (e)  T2 weighted axial images of 
brain (left) and FLAIR images (right) at Month 20 after third dose of alemtuzumab show a large lesion 
in right parietal and posterior frontal white matter that extends to posterior corpus callosum and a 
smaller lesion in left parietal white matter.  (f) Both lesions show an incomplete peripheral rim of 
enhancement on T1 weighted post-gadolinium axial image (left) and coronal image (right). 
Case 3 (g) Pre-treatment T2 weighted sagittal MRI sequence (left) show subtle expansion of cervical 
cord from C2 to C6 inclusive with diffuse increase in signal, more localised at level of C3/4 as 
demonstrated on axial view (right).  (h) T1 weighed sagittal and axial sequences with gadolinium 
contrast show enhancement involving the left side of the cord. Worsening of disease at month 5 after 
alemtuzumab is shown by (i)  T2 weighted sagittal views of spine showing progression of T2 signal 
change and swelling in cervical cord (left) and new thoracic hyperintensity extending from T2 to T7 
(right); with gadolinium enhancement (j). (k) T2 weighted sagittal view of cord shows patchy increased 
intensity and evidence of cord atrophy, 7 years after disease onset. 
 
 
